|
|
商品名 |
|
|
商品名仅供参考, 药品所用的辅料可能依国家或厂商不同有所不同。
|
Asinib |
墨西哥 |
Axinotecan |
德国 |
Campto |
丹麦, 伊朗, 克罗地亚, 匈牙利, 南非, 卢森堡, 印度, 土耳其, 奥地利, 希腊, 意大利, 挪威, 摩洛哥, 日本, 比利时, 法国, 波兰, 泰国, 爱尔兰, 瑞典, 瑞士, 突尼斯, 芬兰, 英国, 荷兰, 葡萄牙, 西班牙, 阿联酋, 马来西亚 |
Camptosar |
加拿大, 巴西, 美国 |
Irinoliquid |
奥地利 |
Irnocam |
巴西 |
|
|
|
|
引用文献 : Irinotecan |
|
|
种类 |
出版物 |
1423 |
文献 |
Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
1617 |
文献 |
Li WY, Koda RT. Stability of irinotecan hydrochloride in aqueous solutions. Am J Health-Syst Pharm 2002 ; 59: 539-544. |
1662 |
文献 |
Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37. |
1918 |
文献 |
Dodds HM, Craik DJ, Rivory LP. Photodegradation of irinotecan (CPT-11) in aqueous solutions : identification of fluorescent products and influence of solution composition. J Pharm Sci 1997 ; 86, 12: 1410-1416. |
1920 |
文献 |
Akimoto K, Kaway A, Ohya K et al. Photodegradation reactions of CPT-11, a derivative of campothecion, part i: chemical structure of main degradation products in aqueous solution. Drug Stability 1996 ; 1: 118-122. |
1921 |
文献 |
Akimoto K, Kawai A, Ohya K. Photodegradation reactions of CPT-11, a derivative of campothecion, part ii: photodegradation behaviour of CPT-11 in aqueous solution. Drug Stability 1996 ; 1; 141-146. |
1953 |
文献 |
Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
1976 |
文献 |
Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with topotecan hydrochloride and irinotecan hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 238-241. |
2027 |
文献 |
Walker SE, Shirley L, Puodziunas A. Simulation of Y-site compatibility of irinotecan and leucovorin at room temperature in 5% dextrose in water in 3 different containers. Can J Hosp Pharm 2005 ; 58: 212-222. |
2143 |
文献 |
Dodds HM, Robert J, Rivory LP. The detection of photodegradation products of irinotecan (CPT-11, Campto®, Camptosar®), in clinical studies, using high-performance liquid chromatography/atmospheric pressure chemical ionisation/mass spectrometry. J Pharm Biomed Anal 1998 ; 17: 785-792. |
2168 |
文献 |
Ozdemir FA, Anilanmert B, Pekin M. Spectrophotometric investigation of the chemical compatibility of the anticancer irinotecan-HCl and epirubicin-HCl in the same infusion solution. Cancer Chemother Pharmacol 2005 ; 56, 5: 529-534. |
2241 |
文献 |
Thiesen J, Krämer I. Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags. J Oncol Pharm Practice 2000 ; 6, 3: 115-121. |
2340 |
文献 |
Walker S.E, Law S, Puodziunas A. Simulation of Y-Site Compatibility of Irinotecan and Leucovorin at Room Temperature in 5% Dextrose in Water in 3 Different Containers Can J Hosp Pharm 2005 ; 58, 4: 212-222. |
2671 |
文献 |
Kaiser J, Thiesen J, Krämer I. Stability of irinotecan-loaded eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Practice 2010 ; 16: 53-61. |
3129 |
实验室 |
Irinotécan (Campto®) – Résumé des caractéristiques du produits Pfizer 2008 |
3369 |
实验室 |
Levofolinate de sodium Medac - Résumé des caractéristiques du produits MEDAC France 2011 |
3670 |
文献 |
Sewell G, Massimini M. Studies on the stability and compatibility of cytotoxic drug infusion with the Tevadaptor system. EJOP 2014 ; 8, 3: 26-30. |
3873 |
文献 |
Tan X, Hu J. Incompatibility between irinotecan and fluorouracil injections Am J Health-Syst Pharm 2016 ; 73:755. |
|
|